RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 4

Registered title, quoted from ClinicalTrials.gov

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of USTC; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07150624, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III.

    Inclusion criterion 5

  3. No history of portal vein embolization prior to enrollment. If TACE treatment was previously received, it must have been completed > 6 months ago; if systemic anti-tumor drug therapy was previously received, it must have been completed > 4 weeks ago.

    Inclusion criterion 9

  4. Preoperative ALT < 2x ULN (upper limit of normal).

    Inclusion criterion 8

  5. Pregnant and lactating women

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07150624, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection.
  • Surgical scope (defined by randomization stratification):Stratum 1: Major hepatectomy, involving the resection of at least 3 Couinaud liver segments, including right hemihepatectomy and extended right hemihepatectomy, etc.Stratum 2: Minor hepatectomy, involving the resection of no more than 2 Couinaud liver segments. This includes right posterior sectorectomy, right anterior sectorectomy, left lateral sectionectomy, single segmentectomy, etc.
  • During the operation, the Pringle method is used to block the first hepatic portal. Each block lasts ≤ 15 minutes, and the blocking procedure is performed 2 to 4 times.
  • Age: 18 - 80 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg/m².
  • Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III.
  • Preoperative ICG R15 < 10%, and the residual liver volume/standard liver volume > 40%.
  • A single HCC (hepatocellular carcinoma), with a tumor diameter of less than 10 cm, without distant metastasis or invasion of the portal vein system.
  • Preoperative ALT < 2x ULN (upper limit of normal).
  • No history of portal vein embolization prior to enrollment. If TACE treatment was previously received, it must have been completed > 6 months ago; if systemic anti-tumor drug therapy was previously received, it must have been completed > 4 weeks ago.
  • No liver-damaging treatment drugs were used within two weeks prior to enrollment.

Exclusion Criteria:

  • Reserve liver vascular damage, including: reconstruction after severance, ligation, embolization, thrombosis, etc
  • Combined with abnormal coagulation function (prothrombin time prolonged by more than 3 seconds)
  • Combining obstructive jaundice, severe heart disease, severe kidney disease and other serious illnesses
  • During the operation, microwave treatment or a combination of microwave treatment was adopted
  • More than 4 times of blocking at the first hepatic hilum, or a single blocking duration longer than 15 minutes
  • Non-anatomic liver resection, where the remaining liver contains large areas of ischemic/edematous regions
  • More than 1000ml of blood transfusion during the operation
  • During the operation, an extra-hepatic disease was discovered. Other organs except the gallbladder needed to be removed simultaneously
  • During the operation, other intrahepatic lesions were discovered, which required combination with other surgeries, such as ablation or choledochojejunostomy
  • Diseases that have previously received systemic treatment with glucocorticoids, such as chronic kidney disease, inflammatory diseases, or other immune system-related disorders
  • Psychosis, severe neurosis, those who cannot cooperate with this experiment
  • Participated in other clinical trials within the previous 3 months before enrollment
  • Allergy or intolerance to benzoic acid, or to the study drug
  • Pregnant and lactating women
  • The researchers believe that any participants who have any other factors that would make them unsuitable for this trial should not be included

Quoted from ClinicalTrials.gov, NCT07150624, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07150624, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07150624